Korean biotech developing udenafil, a PDE5-inhibitor drug studied for single-ventricle heart disease in Fontan-procedure patients.
Korean biotech developing udenafil, a PDE5-inhibitor drug studied for single-ventricle heart disease in Fontan-procedure patients.
Has no approved product of its own, so it relies on raising money from investors while its trials proceed. Udenafil already sells in some countries for erectile dysfunction, which lets it draw on an existing safety record for the heart indication.
Moat: narrow (IP / patents). Patented use of udenafil in a rare pediatric heart condition, backed by US clinical trial data.
Headquarters: Seoul, South Korea · Employees: 18
Size Mezzion Pharma (140410.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.43B, the 183rd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩64,800 on 18 Nov 2026.
Performance Over six months the shares fell 14.6%, against -14.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 12.5% over the last twelve months (peer median +9.6%); the operating margin is -210.6% (peer median 10.9%).
Valuation It trades at 216.0× enterprise value to sales against a peer median of 3.6× (2nd most expensive of 19).
Capital Return on invested capital runs 54.3 points below its cost of capital (7.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩8.72B | ₩7.91B | ₩8.61B | ₩31.7B | ₩30.7B |
| Revenue growth | — | -8% | -73% | +3% | — |
| Gross profit | ₩675M | ₩464M | ₩953M | ₩2.59B | -₩1.60B |
| EBITDA | -₩17.5B | -₩15.8B | -₩13.3B | -₩12.9B | -₩21.7B |
| Net income | -₩29.7B | -₩34.9B | -₩19.5B | -₩12.7B | -₩36.3B |
| Free cash flow | -₩24.3B | -₩16.7B | -₩19.1B | -₩11.6B | -₩12.8B |
| Capital expenditure | ₩7.27B | ₩13.3B | ₩13.5B | ₩11.9B | ₩1.76B |
| Total debt | ₩13.1B | ₩11.9B | ₩1.62B | ₩2.24B | ₩3.71B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 140410.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.4% | -4.1% | 4th highest of 20 |
| 6-month return | -14.6% | -14.7% | 10th highest of 20 |
| Distance from 52-week high | -64.0% | -40.8% | 4th lowest of 20 |
| Revenue growth (TTM) | +12.5% | +9.6% | 9th highest of 19 |
| Operating margin | -210.6% | 10.9% | 5th lowest of 19 |
| EV / Sales | 216.0× | 3.6× | 2nd most expensive of 19 |
| ROIC minus cost of capital | -54.3 pp | -0.5 pp | 7th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | 216.0× | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | 85,633.6× | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 3.8× | 31.0% | +16.6% |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 0.8× | -18.1% | +7.0% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 1.4× | -6.4% | +12.7% |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 3.1× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 8.9× | 36.3% | +16.6% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 2.1× | -9.6% | +4.6% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | 17.0× | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | 46.5× | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | 125.0× | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | 3.5× | -4.9% | +0.2% |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | 146.3× | n/a | n/a |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 1.4× | -6.1% | +1.9% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 3.0× | 3.9% | +22.8% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | 4.7× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | 3.0× | 10.2% | +18.1% |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 9.6× | 25.9% | +23.1% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | 0.9× | -6.8% | +32.4% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |